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Abstract
Background: The development of novel influenza vaccines inducing a broad immune response is an important objective.
The aim of this study was to evaluate live vaccines which induce both strong humoral and cell-mediated immune responses
against the novel human pandemic H1N1 influenza virus, and to show protection in a lethal animal challenge model.
Methodology/Principal Findings: For this purpose, the hemagglutinin (HA) and neuraminidase (NA) genes of the influenza
A/California/07/2009 (H1N1) strain (CA/07) were inserted into the replication-deficient modified vaccinia Ankara (MVA) virus
- a safe poxviral live vector – resulting in MVA-H1-Ca and MVA-N1-Ca vectors. These live vaccines, together with an
inactivated whole virus vaccine, were assessed in a lung infection model using immune competent Balb/c mice, and in a
lethal challenge model using severe combined immunodeficient (SCID) mice after passive serum transfer from immunized
mice. Balb/c mice vaccinated with the MVA-H1-Ca virus or the inactivated vaccine were fully protected from lung infection
after challenge with the influenza H1N1 wild-type strain, while the neuraminidase virus MVA-N1-Ca induced only partial
protection. The live vaccines were already protective after a single dose and induced substantial amounts of neutralizing
antibodies and of interferon-c-secreting (IFN-c) CD4- and CD8 T-cells in lungs and spleens. In the lungs, a rapid increase of
HA-specific CD4- and CD8 T cells was observed in vaccinated mice shortly after challenge with influenza swine flu virus,
which probably contributes to the strong inhibition of pulmonary viral replication observed. In addition, passive transfer of
antisera raised in MVA-H1-Ca vaccinated immune-competent mice protected SCID mice from lethal challenge with the CA/
07 wild-type virus.
Conclusions/Significance: The non-replicating MVA-based H1N1 live vaccines induce a broad protective immune response
and are promising vaccine candidates for pandemic influenza.
Citation: Hessel A, Schwendinger M, Fritz D, Coulibaly S, Holzer GW, et al. (2010) A Pandemic Influenza H1N1 Live Vaccine Based on Modified Vaccinia Ankara Is
Highly Immunogenic and Protects Mice in Active and Passive Immunizations. PLoS ONE 5(8): e12217. doi:10.1371/journal.pone.0012217
Editor: Samithamby Jeyaseelan, Louisiana State University, United States of America
Received January 18, 2010; Accepted July 11, 2010; Published August 16, 2010
Copyright:  2010 Hessel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by Baxter BioScience. The funders were involved in study design, data collection and analysis, decision to publish, and
preparation of the manuscript.
Competing Interests: All authors are employees of Baxter BioScience, a manufacturer of biologicals including influenza vaccines. AH, MS, OK, TRK, BAC, PNB
and FGF are shareholders of Baxter. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: falknef@baxter.com
Introduction
Influenza virus infection is a non-eradicable zoonosis and
therefore pandemics caused by novel influenza A subtypes are a
permanent threat (for review see: [1]). Despite the emergence and
spread of the highly pathogenic avian H5N1 virus since 1997 and
the absence of H2 strains from human circulation since 1968, the
first pandemic of this century was not caused by H5 or H2
subtypes but by the novel swine-origin H1N1 strains first detected
in humans in April 2009. The global spread of the novel H1N1
influenza subtype has made the development of vaccines a global
public health priority. Several strategies are currently being
followed to produce pandemic vaccines, such as the development
of inactivated whole virus vaccines, subunit vaccines, recombinant
viral proteins and live vaccines. Vaccines based on inactivated
influenza virus are usually derived from embryonated hens’ eggs
or, more recently, from permanent cell cultures. Protective
immunity elicited by these vaccines is mainly based on neutralizing
antibodies directed against the HA (reviews: [2,3]).
However, a more broad immune response which includes
efficient antibodies against the influenza surface proteins as well as
induction of CD8 T cells – as accomplished by live vaccines -
would be desirable. Attenuated live vaccines such as cold-adapted
influenza strains [4,5] or nonreplicating, NS-1 gene-deleted
influenza virus [6,7] presumably have these advantages. Intranasal
application of such pre-pandemic live vaccines might, however,
result in new reassortant strains by co-infections in the respiratory
tract with wild-type influenza strains, thereby raising safety
concerns. Moreover, in certain instances, influenza reassortants
of the cold-adapted internal gene backbone with avian strains have
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subpotent immune responses [8]. Only the re-introduction of the
polybasic cleavage site into the HA (previously deleted to attenuate
the live virus) restored infectivity and immunogenicity [9]. In
another case, passaging of the live vaccine in host cells was
required to achieve acceptable growth. Passaging, however, may
result in reduced immunogenicity that may require screening of
adequate reassortants [8]. Finally, the long-term effect of repeated
intranasal administration of high doses of live virus vaccines on the
olfactory system is largely unknown.
To circumvent these issues, live vaccines based on nonreplicat-
ing poxviral vectors - such as the highly attenuated MVA vector –
are a promising alternative. These vectors have a long-standing
safety record, induce excellent T cell responses and are usually
administered by reliable subcutaneous or intramuscular routes.
The purpose of this study was to evaluate the immune response
and the protective potential of MVA-based influenza vaccines
expressing the protective antigens hemagglutinin and neuramin-
idase of the novel H1N1 strain. Efficient induction of antibodies
and surprisingly high levels of CD8 T cells were induced against
both antigens.
Materials and Methods
Ethics statement
All animal experiments were reviewed by the Institutional
Animal Care and Use Committee (IACUC) and approved by the
Austrian regulatory authorities. All animal experiments were
conducted in accordance with Austrian laws on animal experi-
mentation and guidelines set out by the Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC).
Animals were housed in facilities accredited by the AAALAC.
Cells and viruses
The Vero (CCL-81) and DF-1 (CRL-12203) cell lines were
obtained from the American Type Culture Collection. They were
cultivated in DMEM (Biochrom AG) containing 5% fetal calf
serum (FCS). Chicken embryo cells (CEC) were cultivated in
M199 (Gibco, Inc.) containing 5% fetal calf serum (FCS). Madin-
Darby canine kidney (MDCK) cells were maintained serum free in
Ultra-MDCK medium (Bio Whittaker). The influenza virus A/
California/07/2009 (H1N1; CDC#2009712112) was kindly
provided by the Centers for Disease Control and Prevention
(CDC, Atlanta, USA). The vaccinia virus strain Lister/Elstree
(VR-862) was obtained from the American Type Culture
Collection. The basis of the Lister constructs was the subcloned
virus vpDW-862/Elstree [10]. The MVA strain (MVA 1974/NIH
clone 1) was kindly provided by B. Moss (National Institutes of
Health).
Cloning and sequencing of hemagglutinin and
neuraminidase genes
The hemagglutinin (Genbank #FJ966082) and neuraminidase
(Genbank #FJ966084) sequences of A/California/7/2009 were
synthesized (Geneart, Regensburg, Germany). Both synthetic
genes are driven by the strong early/late vaccinia virus promoter
mH5 and terminate with a vaccinia virus specific stop signal
downstream of the coding region that is absent internally. Both
expression cassettes were cloned into the MVA transfer plasmid
pHA-vA [11] resulting in pHA-mH5-H1-Ca and pHA-mH5-N1-
Ca, respectively. The insertion plasmids direct the gene cassettes
into the MVA HA-locus, close to deletion III of MVA [12,13].
Both gene cassettes were inserted in parallel into the vaccinia
transfer plasmid pER-mH5-PL resulting in pER-mH5-H1-Ca or
pER-mH5-N1-Ca, respectively. The plasmid pER-mH5-PL was
obtained by insertion of the vaccinia virus promoter mH5, a
vaccinia virus stop signal (TTTTTNT) and a multiple cloning site
(StuI, NcoI, PvuII, SpeI, HindIII, SacI, XmaI, SalI, NotI) into
plasmid pER that directs the gene cassette into the D4/D5
intergenic region [14].
Construction of recombinant vaccinia viruses
rVVL-H1-Ca and rVVL-N1-Ca. Twenty micrograms of
pER-mH5-H1-Ca or pER-mH5-N1-Ca plasmid DNA were
transfected into vaccinia virus Lister-infected Vero cells by
calcium phosphate co-precipitation and further processed as
described previously [14]. Plaque isolates were purified three
times and expanded for large scale preparations in Vero cells. The
vaccinia virus stocks were prepared in Vero cells by infection with
0.1 MOI for 72 hours. Infected cells were harvested and sucrose
cushion purified viral stocks were prepared [14].
MVA-H1-Ca and MVA-N1-Ca. Twenty micrograms of
pHA-mH5-H1-Ca or pHA-mH5-N1-Ca plasmid DNA were
transfected into MVA infected CEC by calcium phosphate
precipitation and further processed as described previously [11].
The purified recombinant virus isolates were expanded for large
scale preparations in CEC.
Western blot analysis
Expression of the H1 or N1 proteins by recombinant vaccinia
viruses was detected by Western blotting. Vero cells in case of the
VV-L constructs, or the avian cell line DF-1 [15] in case of MVA,
wereinfected at a multiplicityofinfectionof 0.1for48 h.MVA-H1-
Ca or rVVL-H1-Ca infected cells were harvested by scraping or by
adding trypsin. MVA-N1-Ca or rVVL-N1-Ca infected cells were
harvested by scraping. Sonicated cell lysates were loaded onto 12%
polyacrylamide gels (BioRad, Inc) and afterwards blotted on
nitrocellulose membrane (Invitrogen, Inc). To detect the H1
protein, a sheep antiserum against the A/California/7/2009
hemagglutinin (NIBSC 09/152) was used. Donkey-anti-sheep
alkaline phosphatase-conjugated IgG (Sigma Inc.) was used as a
secondary antibody. To detect the N1 protein a polyclonal rabbit
anti avian influenza A neuramindase (Abcam, ab21304) was
utilized. Goat-anti-rabbit alkaline phosphatase-conjugated IgG
(Sigma Inc.) was used as a secondary antibody. A whole virus
vaccineH1N1A/California/7/2009[16] servedaspositivecontrol.
Immunizations of Balb/c mice for analysis of humoral
immunity
Groups of 6 female Balb/c mice (8–10 weeks old) were immunized
intramuscularly either once (day 0) or twice (days 0 and 21) with 10
6
or 10
7 pfu of recombinant MVA-H1-Ca or rVV-L-H1-Ca. Control
groups were immunized with 10
7 pfu wild-type MVA, 10
7 pfu wild
type VV-L, 3.75 mg of whole virus vaccine H1N1 A/California/7/
2009 (inact. H1N1) or with PBS buffer. Mice were challenged
intranasally with 10
5TCID50 per animal of A/California/7/2009 on
day 42 and lungs were removed three days later and frozen at #60uC
for virus titer determination. Blood samples were taken to measure
HA-specific IgG concentration and HI titer on days 20 and 41.
Immunizations of Balb/c mice for analysis of cellular
immunity
Groups of 6 female Balb/c mice (8–10 weeks old) were
immunized intramuscularly on days 0 and 21 with 10
6 pfu of
recombinant MVA-H1-Ca or rVVL-H1-Ca, wild-type MVA or
VV-L, 3.75 mg of whole virus vaccine H1N1 A/California/7/
2009 (inact. H1N1) or with PBS buffer. Spleens were obtained for
MVA Pandemic H1N1 Vaccine
PLoS ONE | www.plosone.org 2 August 2010 | Volume 5 | Issue 8 | e12217IFN-c analyses at day 28 post-immunization. Furthermore, groups
of 5 mice immunized two times with 10
6 pfu of recombinant
MVA-H1-Ca, rVVLH1-Ca, or MVAwt were challenged intrana-
sally with 10
5 TCID50 per animal of A/California/7/2009 on day
42, and lungs and spleens were collected after euthanizing the
mice 7 days after the booster immunization (day 28), at the time of
challenge (day 41) or three days thereafter (day 45) for
determination of influenza-specific T-cell frequencies.
Preparation of the lung samples for virus titration
Mice were euthanized and lungs were removed on day 3 post
challenge with wild-type H1N1 virus. These tissue samples were
stored at ,260uC until they were transferred into homogeniza-
tion tubes (Precellys Ceramic Kit 2.8 mm, PEQLAB Biotechno-
logie GmbH) containing 1 ml cell medium supplemented with
antibiotics. The lungs were homogenized two times at 5000 rpm
for twenty seconds with 5 seconds pause between the intervals with
a tissue homogenizer (Precellys24, PEQLAB Biotechnologie
GmbH). The infectious H1N1 virus titer in homogenized lung
samples was determined by a TCID50 assay performed by
titration on Madin-Darby canine kidney (MDCK) cells by serial
ten-fold dilutions of samples as described [17].
Passage assay of low-titer lung samples in MDCK cells
Lung samples with titers #3 log10 TCID50 were verified by
this passage assay. Confluent MDCK cells (grown in 75 cm
2 Roux
flasks) were infected with 100 ml of mouse lung sample. The
adsorption medium was 10 ml Ultra MDCK-Medium (BioWhit-
taker) and contained 1 mg/ml TPCK trypsin (Sigma-AldrichH).
After one hour virus adsorption 40 ml Ultra MDCK-Medium
supplemented with 1 mg/ml TPCK trypsin was added and the
infection was further incubated for 6 days. Afterwards the MDCK
cells were analysed for infection. The detection limit of the assay,
determined by spiking with 100, 10 and 1 TCID50 virus per flask,
was approximately 1 TCID50/ml.
Determining the lethal challenge dose of H1N1 wt in
SCID mice
To define the lethal challenge dose 50 (LD50) of wt H1N1 A/
California/7/2009 virus in severe combined immunodeficient
(SCID) mice, 4–5 week old female SCID mice (strain CB17/Icr-
Prkdcscid/IcrCrl; Charles River, Sulzfeld, Germany) were used.
Mice were challenged intranasally (10 ml) with 10-fold serial
dilutions of the wt A/California/7/2009 (H1N1) strain. The virus
dose that kills 50% of the SCID mice (lethal dose 50, LD50) was
calculated by the software program Graph-Pad Prism 5.
H1N1 challenge and passive protection of SCID mice
For generation of sera for passive transfer studies, CD1 mice
(Charles River) were immunized twice (d0, d21) with 10
6 pfu
recombinant MVA-H1-Ca, rVVL-H1-Ca, MVA wt or 3.75 mgo f
whole virus vaccines H1N1 A/California/07/2009 (inact. H1N1),
respectively. Serum pools were prepared on day 42 and analysed
via HI and ELISA. For passive protection experiments, 200 mlo f
the produced sera were injected intraperitoneally into 4–5 week
old SCID mice. One or two days afterwards, mice were challenged
by intranasal instillation with 10
5 TCID50 per animal of the A/
California/07/2009(H1N1) wild-type strain and monitored for
clinical parameters and survival for 30 days.
Hemagglutination Inhibition (HI) Assay
The HI titer of the sera was determined using chicken
erythrocytes as described [17]. Briefly, sera were treated with
receptor destroying enzyme, inactivated at 56uC and two-fold
serially diluted. Sera were incubated with formalin-inactivated A/
California/07/2009 virus standardized to 8 HA units/50 ml [18]
followed by incubation with erythrocytes. The detection limit was
a HI titer of #10.
Neuraminidase Inhibition (NI) Assay
Anti-neuraminidase serum antibodies were measured with a
modified, miniaturized neuraminidase inhibition assay [19].
Briefly, serially diluted inactivated H1N1 A/California/07/2009
wild-type virus preparation was mixed with an equal volume of
fetuin [25 mg/mL] and incubated for 18 h at 37uC. After addition
of periodate and incubation for 20 min, arsenite was added and
the solution mixed until the brown colour disappeared. Thiobar-
bituric acid was then added and samples boiled for 15 min. The
pink reaction product was extracted by butanol and its absorbance
determined at 550 nm using a reaction blank as reference. The
half-maximal neuraminidase activity (EC50) was determined using
non-linear regression of the absorbance data (GraphPad Prism,
GraphPad Software, USA). For the subsequent neuraminidase
inhibition studies, the concentration of the virus was adjusted to an
equivalent of half-maximal neuraminidase activity. Serially diluted
sera were incubated with the appropriately diluted virus
preparation for 1 h and the neuraminidase activity determined
as described above. The neuraminidase inhibition titer was
defined as the reciprocal serum dilution at which neuraminidase
activity was 50% inhibited.
Preparation of single cell suspensions from spleens or
lungs of immunized and challenged mice
Single cell suspensions of splenocytes were obtained by grinding
5 spleens per group through a metal mesh into culture media (45%
RPMI1640 [Gibco], 45% CLICKs Medium [Sigma], 10% FCS
[Gibco], Penicillin-Streptomycin [Gibco], 2 mM L-glutamine
[Gibco]). Splenocytes were either used immediately or were
frozen in Cryostor CS-10 (VWR). Single cell preparations were
also obtained from the lungs of immunized mice before and after
challenge with H1N1 swine flu virus. After euthanizing the mice,
lungs were flushed by injecting 0.5–1 ml of PBS/Heparin (5 IE/
ml) into the right ventricle of the heart. The lungs were then
removed and immediately placed into culture media, cut into
small pieces and digested for 25 min at RT by adding 5 mM
MgCl2 [Merck], 150 Units/ml DNAse I [Roche] and 1 mg/ml
collagenase XI [Sigma] to the culture media. After digestion, the
remaining pieces were ground through a metal mesh into culture
media, and the resulting cell suspension was filtered through a
70 mm nylon mesh [BD]. Residual red blood cells were removed
using RBC lysis buffer [Sigma] according to the manufacturer
instructions, and the cells were used immediately for FACS-based
IFN-c analyses.
T-cell IFN-c analysis
Peak response frequencies of vaccine-specific IFN-c producing
T-cells in Balb/c mice were determined by flow cytometric
intracellular cytokine staining in spleens 7 days after the second
immunization, or in lungs on the day before challenge (day 41) or
3 days after challenge (day 45). Approximately 2610
6 cells were
dispensed into 96-well round-bottom-plates (Costar) and stimulat-
ed for approximately 14 h at 37uC with vaccine antigens (H1N1/
California/07/2009, H1N1/Brisbane/59/2007, H1N1/New Ca-
ledonia/20/99, H5N1/Vietnam/1203/2004) at 3 mg/mL hem-
agglutinin, or with peptide pools of 15-mers overlapping by 10
amino acids at 2 mg/ml per peptide. Two pools of 111 and 92
MVA Pandemic H1N1 Vaccine
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California/07/2009, respectively. Cells incubated with medium
alone served as a negative control. After 2 h 10 mg/ml brefeldin A
(Sigma) was added to inhibit secretion of cytokines and further
incubated for 12 h. Then, cells were resuspended in 50 mM PBS/
EDTA, and stained with LIVE/Dead Violet Kit (VIVID,
Molecular Probes) diluted 1:10000 in PBS for 15 min at room
temperature. Cells were washed and incubated with rat anti-
mouse CD4-APC antibody (BD Biosciences, 0.4 mg/mL), and
CD8-APC H7 antibody (BD Biosciences, 1.5 mg/ml) for 10 min at
room temperature. After washing and fixation with 1% parafor-
maldehyde (Merck), cells were permeabilized in PBS supplement-
ed with 0.08% saponin (Sigma), and incubated with rat anti-mouse
IFN-c FITC antibody, (BD Biosciences, 0.5 mg/mL) and rat anti-
mouse CD3-PerCP (BD Biosciences, 1.5 mg/mL) for 30 min at
room temperature. Finally, cells were washed and fixed with 1%
paraformaldehyde. At least 100.000 viable cells were applied on a
FACSCanto-2 (BD Biosciences), and data analysis was performed
using the FlowJo software (Tree Star, Inc.). Percentages of IFN-c
producing T-cells were calculated after gating on VIVID negative,
CD3 positive, CD4 or CD8 positive lymphocytes.
Microneutralization assay
The microneutralization assay was done as described previously
[16]. Briefly, sera was diluted and mixed with the A/California/7/
09 virus strain at a concentration of 4.5 log TCID50/ml. The
mixture was incubated for six days on MDCK monolayer before
cells were inspected for cytopathic effects. The neutralizing
antibody titer was defined as described [16].
Statistical analysis
For statistical comparison of lung titers the Tukey test was used.
The data of T cell responses were statistically analyzed using the
two-way ANOVA. Survival differences between animal groups
were analyzed using the Kaplan Meyer log rank test of GraphPad
Prism software (San Diego, CA). All differences were considered
significant at P values ,0.05.
Results
1. Construction and characterization of the MVA viruses
The HA and NA genes of the influenza strain A/California/07/
2009 (H1N1) were placed downstream of a strong vaccinia early/
late promoter [20] and the resulting plasmids were used to
construct the viruses MVA-H1-Ca and MVA-N1-Ca by in-vivo
recombination techniques using transient marker genes. Replicat-
ing control viruses based on the vaccinia Lister strain, rVVL-H1-
Ca and rVVL-N1-Ca, respectively, were also constructed (see
Table 1 and Methods). The H1 and N1 genes were synthetic
genes optimized for expression in vaccinia virus, lacking internal
transcription stop signals [21]. The virus constructs were
characterized by PCR for absence of wild-type virus and for
presence of the HA and NA gene inserts (data not shown).
Next, expression of the influenza genes in avian cells was
analyzed. Since parameters such as temporal order and level of
gene expression and processing of the protective antigen influence
immune responses in vaccinia-based live vaccines, western blot
analyses with lysates of infected cells were performed. In infected
target cells of the respiratory tract, the influenza hemagglutinin
precursor (HA0) is cleaved by intracellular proteases into the
heterodimeric receptor molecule (HA1 and HA2) resulting in full
infectivity of influenza virus. In order to assess HA antigen levels
and processing, expression experiments in MVA-permissive avian
cells were performed. Total cell lysates were analyzed by PAGE
and Western blotting using anti-hemagglutinin sera. As shown in
Fig. 1A, the viruses with HA gene inserts induced high level
expression of HA in avian DF-1 cells. The large band at around
80 kDa represents the HA0 hemagglutinin-precursor, which is not
cleaved in cells lacking the required proteases such as the chicken
cells used to propagate MVA (lanes 4 and 6). To further
characterize the HA0 precursor, the cell lysates were treated with
trypsin (see Methods). In both, the rVVL-H1-Ca and the MVA-
H1-Ca infected cells, two novel bands at approximately 64 and
26 kDa appeared that represent the HA1 and HA2 subunits (lanes
5 and 7). The polypeptide pattern of the inactivated whole virus
vaccine is shown in lane 2. The HA-specific bands in this control
co-migrate with the ones expressed by the viral vectors. In the
negative controls these bands are absent (lanes 3, 8, 9). In mouse
muscle cells, infected with the same HA containing vectors and
controls, the HA0 band could be seen, that was cleaved into the
two subunits only upon trypsin treatment. Thus, the same
expression pattern was obtained in MVA-permissive avian cells
and in non-permissive murine cells that presumably reflect the
situation in mice vaccinated by the intramuscular route (data not
shown).
To reveal the expression pattern of the neuraminidase
constructs, lysates of infected DF-1 cells together with controls,
were subjected to Western blotting and probed with an antibody
raised against a peptide present in the neuraminidases of different
subtypes including N1 and N5 (see Methods). The recombinant
vectors induced a broad novel band in the 75 kDa range,
representing the highly glycosylated neuraminidase of the A/
California/07/2009 (CA/07) strain (Fig. 1B, lanes 4 and 5), that
was also detectable in the inactivated vaccine preparation (lane 2),
but was absent in the negative controls including non-infected and
wild-type virus infected cells (lanes 3, 6, 7). The prominent band in
the 47 kDa size range (lanes 3–7) is a protein present in DF-1 cells
non-specifically cross-reacting with the first antibody.
2. Protection studies in immune competent mice
Protection studies were subsequently carried out in BALB/c
mice. Upon challenge with H1N1 swine flu virus, this mouse strain
develops signs of disease, nevertheless the mice recover after two
weeks [22]. Protection from virus replication in the lungs in this
model was used as the read-out for efficacy. In the protection
Table 1. Viruses, vaccine constructs and controls used in the
study.
vaccine
inserted
flu gene plasmid
Titer
(1)
(pfu/ml)
MVA-H1-Ca hemagglutinin pHA-mH5-H1-Ca
(2) 4.0610
9
MVA-N1-Ca neuraminidase pHA-mH5-NA-Ca 1.6610
9
rVVL-H1-Ca hemagglutinin pER-mH5-H1-Ca 4.3610
9
rVVL-N1-Ca neuraminidase pER-mH5-NA-Ca 7.4610
9
VVL-wt
(3) empty vector n.a. 1.7610
11
MVA-wt
(4) empty vector n.a. 5.0610
9
Inact. H1N1
(5) n. a. n.a. n. a.
(1)titers of sucrose-purified virus preparations (see Methods);
(2)influenza genes in VV constructs are controlled by the vaccinia mH5
promoter; HA and NA genes are derived from the influenza CA/07 strain;
(3)wild-type vaccinia Lister strain;
(4)wild-type MVA (NIH74 LVD clone 6);
(5)inactivated whole virus vaccine based on CA/07 strain; n. a., not applicable.
doi:10.1371/journal.pone.0012217.t001
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expressing viral constructs were compared to a formalin-
inactivated whole virus vaccine (inact. H1N1) [16]. The live
vaccines were given by intramuscular injection of 1610
6 and
1610
7 pfu per animal. The dose of the inactivated vaccine was
3.75 mg( Table 2). The groups were boosted after 21 days and all
groups were challenged at day 42. Groups of mice immunized
with the empty vectors (MVA-wt and VVL-wt) and with
phosphate buffered saline (PBS) served as negative controls. The
challenge virus was given intranasally at a dose of 1610
5 TCID50
per animal. Three days after challenge the lungs were removed
and virus titers were determined. The results of the lung titrations
are shown in Fig. 2 and in Table 2. In the groups immunized
with the hemagglutinin constructs, MVA-H1-Ca or rVVL-H1-Ca,
protection from lung virus was almost complete; 92–100%
protection was achieved, depending on dose and construct
(Table 2, groups 1–4). This protection was significantly higher
compared to the control groups immunized with PBS or empty
vectors (P,0.0001). Hemagglutinin-inhibition (HI) titers of the
mouse sera, performed using the purified swine flu virus as
hemagglutinin, were in the range of 453–905. Neutralization titers
were also high, i.e. in the range of 761–1076.
With the neuraminidase construct, MVA-N1-Ca, partial
protection was achieved. Even in the unprotected mice the lung
virus titers were rather low, indicating that some degree of
protection was achieved also in these animals (Fig. 2 and
Table 2, groups 5–6). With the replicating vaccinia construct,
rVVL-N1-Ca, full protection was seen at both doses (Table 2,
groups 7–8). Neuraminidase-inhibiting antibodies were high after
immunization with the viral constructs expressing NA, and absent
in the HA constructs used as controls. As expected, the HI titers
were below the detection limit. Mice immunized with the
inactivated vaccine were almost fully protected with HI titers of
640 and NI titers of 256 (Table 2, group 9). Mice injected with
the negative controls, empty MVA and VVL vectors and PBS,
were not protected and sera were negative for HI and NI
antibodies (groups 10–12). The number of protected mice in the
groups immunized either with inactivated vaccine, or the live
vaccines was significantly higher as compared to the controls
(P,0.0001).
In addition, protection was also studied after single dose
immunizations (dose 10
6 TCID50 per animal) with the HA and
NA constructs. As before, the challenge was carried out at day 42.
In case of the HA viruses, 100% and 83% protection was achieved
with the replicating vaccinia vectors and with the MVA-based
vaccines, respectively. In case of the NA viruses, protection was
less efficient, 33% and 67% protection was obtained with the
replicating and the nonreplicating vectors, respectively.
3. Induction kinetics of antibody responses
Since induction of rapid immunity is crucial for pandemic
vaccines, the kinetics of antibody induction against the major
protective antigen, the hemagglutinin, was determined after single
dose vaccinations. For this purpose, mice were immunized with
increasing doses (range 10
6 to 10
8 pfu/animal) of the H1
containing vectors and with appropriate controls. Sera were taken
each week over a period of 70 days, pooled by groups and
analyzed using the HI- and mNT-test (Table 3). With MVA-H1-
Ca, the first HI antibodies were detectable at day 7 (Table 3,
group 3), at that time point the neutralizing antibodies were
below the detection limit. Apparently independent of dose, both,
neutralizing and HI antibodies were found after day 21. In the
examined dose range, titers increased over time, however no clear
dose dependence was seen. The titers induced by the replicating
control, rVVL-H1-Ca, were clearly dose dependent. NT and HI
titers were detectable starting at day 7 in the 10
8 pfu dosage group
(Table 3, group 6). Titers increased with time and remained high
over the observation period. With the controls, MVA wt and PBS,
the titers remained below the detection limit.
4. Passive protection studies in severe combined
immune-deficient (SCID) mice
Animal models should reflect the pathology induced in humans.
In the case of the new H1N1 influenza, the model should protect
from typical disease symptoms, such as malaise, pneumonia and
even death. Since immune competent Balb/c mice and the slightly
more susceptible CD1 mice recover from wt H1N1 challenge,
SCID mice were used in the following experiments. For the
passive protection experiments, first, antisera were generated.
Immune competent mice were immunized twice with the MVA-
Figure 1. Western blots of chicken cell (DF-1) lysates probed
for influenza antigens. (A) Hemagglutinin expression in chicken cells.
Lane 1, marker size in kDa. Lane 2, formalin-inactivated purified H1N1
influenza virus. Lane 3, negative control, DF-1 cells infected with wt
vaccinia virus. Lane 4, replicating virus rVVL-H1-Ca, no trypsin
treatment. Lane 5, replicating virus rVVL-H1-CA, with trypsin treatment.
Lane 6, MVA-H1-Ca, no trypsin treatment. Lane 7, MVA-H1-Ca, with
trypsin treatment. Lane 8, negative control lysate, MVA wt virus. Lane 9,
uninfected cell lysate. HA0, unprocessed hemagglutinin; HA1 and HA2,
the two processed HA subunits. B) Neuraminidase expression in chicken
cells. Lanes 1-3, samples as above. Lane 4, replicating virus rVVL-N1-Ca.
Lane 5, MVA-N1-Ca. Lane 6 and 7, negative controls, lysates of MVA wt
virus and non-infected DF-1 cells. The band around 75 kDa represents
the neuraminidase (NA).
doi:10.1371/journal.pone.0012217.g001
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42. The HA-specific sera generated for transfer had HI titers of
640, while the titer of the control serum (MVA-wt vaccinated
mice) was below the detection limit.
The virulence of the new H1N1 strain in SCID mice was
subsequently analyzed. After intranasal challenge with the CA/07
strain, the SCID mice died ina dose-dependent manner.Doses.10
4
TCID50 per animal killed all mice within a four week period
(Fig. 3A). In parallel, SCID mice were treated with the antisera. All
mice treated with the MVA-H1-Ca induced sera were fully protected
from death and disease symptoms while the survival rate of animals
treated with the rVVL-H1-Ca-induced sera was 83%. The control
animals, however, got sick and died in the third and fourth week after
infection (Fig. 3B). In some of the animals protected by the MVA-
H1-Ca induced sera, no virus was found in lungs at the end of the
experiment at day 30. In others, despite lack of clinical symptoms,
virus was present in the lungs (data not shown). Thus, passively
transferred antibodies, induced by the MVA-H1-Ca live vaccine and
the replicating controls, could fully protect micefrom lethal challenge
with the wild-type CA/07 virus confirming the important role of anti-
H1 antibodies in protection from H1N1 influenza. Complete passive
protection of SCID mice from lethal challenge by antisera generated
in mice and guinea pigs with the inactivated H1N1 whole virus
vaccine also used in this study was seen previously [16].
5. Hemagglutinin-specific and cross-reactive T cell
responses in spleens
Subsequently, T cell responses induced by the different vaccines
were characterized in mice immunized twice (days 0 and 21) with
the MVA- and rVVL-H1-Ca and N1-Ca constructs. Splenocytes
were prepared on day 28 and stimulated in-vitro with whole virus
antigens or HA- or NA-specific peptide pools of overlapping 15-
mers covering the entire HA or NA sequence of the CA/07 strain.
The whole virus antigens used for stimulation included the
monovalent vaccine bulks (MVBs) of inactivated influenza
Table 2. Protection of mice from lung viremia and serology results after two vaccinations.
Gr. Virus Vaccine dose [pfu or mg/mouse] Protection n/n total (%) HI-Titer
(1) [GMT
(2)] mNT
(3) [GMT
(2)] NI-Titer
(4) [GMT
(2)]
1 MVA-H1-Ca 10
6 11/12
(5) (92) 453 905 n.d.
2 MVA-H1-Ca 10
7 12/12 (100) 905 1076 n.d.
3 rVVL-H1-Ca 10
6 12/12 (100) 453 761 n.d.
4 rVVL-H1-Ca 10
7 12/12 (100) 640 1076 n.d.
5 MVA-N1-Ca 10
6 9/12 (75) ,dl
(9) n.d. 128
6 MVA-N1-Ca 10
7 4/12 (83) ,dl n.d. 1024
7 rVVL-N1-Ca 10
6 12/12 (100) ,dl n.d. 1024
8 rVVL-N1-Ca 10
7 12/12 (100) ,dl n.d. 2048
9 Inact. H1N1
(6) 3.75 11/12 (92) 640 538 256
10 MVA-wt
(7) 10
7 1/12 (8.3) ,dl ,dl ,2
11 VVL-wt
(8) 10
7 0/12 (0) ,dl n.d. ,2
12 PBS - 0/12 (0) ,dl ,dl ,2
(1)hemagglutinin-inhibition titer determined with chicken erythrocytes;
(2)geometric mean titer;
(3)microneutralization assay (cpe-based);
(4)neuraminidase-inhibition titer;
(5)two separate experiments with 6 animals per group were performed;
(6)inactivated whole virus vaccine, subcutaneous application route;
(7)wild-type MVA (NIH74 LVD clone 6);
(8)wild-type vaccinia Lister strain;
(9)the dectection limit (dl) is ,10;
doi:10.1371/journal.pone.0012217.t002
Figure 2. Lung titers in Balb/c mice. The dots represent the lung titers
of individual mice vaccinated with the different experimental vaccines or
control preparations. Mice vaccinated with the controls (PBS, wild-type
MVA (MVA wt) or Lister (VV-L wt) were not protected showing average
log10 TCID50 titers of 5.2, 4.9 and 5.4, respectively. Mice vaccinated with
inactivated vaccine (inact. H1N1), or two different doses (10
6,1 0
7 pfu) of
MVA-H1-Ca or rVVL-H1-Ca were close to or fully protected. Partial
protection was achieved with two dosages of the MVA neuraminidase
viruses (MVA-N1-Ca), while full protection was seen with the Lister-based
neuraminidase virus (rVVL-N1-Ca). The dotted line represents the detection
limit of log102.21.Low titers in range of log10,2.21 to3.0were confirmed
by a passage assay of the lung samples in MDCK cells.
doi:10.1371/journal.pone.0012217.g002
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Brisbane/59/2007 (H1N1/BR), A/New Caledonia/20/99
(H1N1/NC) and the H5N1 strain A/Vietnam/1203/2004
(H5N1/VN). The frequencies of IFN-c producing T cells were
then determined by FACS-based intracellular cytokine assays.
Differentiation between CD4 and CD8 T cells was achieved by
staining with specific monoclonal antibodies (see methods).
The results obtained with hemagglutinin-containing constructs
MVA-H1-Ca and rVVL-H1-Ca and with the inactivated vaccine
areshowninFig.4.Specificinductionof0.5–0.8%ofCD4Tcells
was seen after homologous stimulation with H1N1/CA antigen of
splenocytes of mice vaccinated with the MVA and VVL-based
vaccines. This specific induction of CD4 T cells was significantly
highercomparedto the MVA wild-typegroup (P,0.05).Significant
levels of cross-reactive T-cells recognizing seasonal H1N1/BR and
H1N1/NC antigen were also detected, whereas no cross-reaction
with pandemic H5N1/VN was induced (P.0.05). When using the
H1 CA/07 peptide pool for stimulation of the splenocytes, 1.3–
1.4% of the CD4 T-cells produced IFN-c secretion in mice
immunized with both the MVA and the VVL-based HA constructs.
As expected, the levels of influenza-specific CD4 T-cells induced by
the inactivated virus were several-fold lower (Fig. 4A).
Furthermore, CD8 T cells induced by the HA constructs were
analyzed. The H1/CA peptide pool stimulated surprisingly high
amounts of CTLs, around 3–5% of total CD8 T cells were specific
for H1, whereas the N1-specific peptide pool used as a negative
control, did not induce significant levels of CD8 T cells (P.0.05),
Fig. 4B). MVA constructs induced slightly higher levels of CD8 T
cells than the Lister constructs. The inactivated vaccine induced
low but measurable amounts of CTLs. The splenocytes of mice
vaccinated with the empty vectors did not react with the HA-
specific antigens and peptides (not shown).
6. Neuraminidase-specific T cell responses in spleens
To investigate neuraminidase-specific T cell responses, mice
were immunized as described above with the neuraminidase-
containing constructs MVA-N1-Ca and rVVL-N1-Ca and with
the controls. The results obtained are shown in Fig. 5. Using the
homologous stimulant, H1N1/CA antigen, induction of about
0.25% of CD4 T cells by the live vectors was achieved. With the
Brisbane (H1N1/BR) and with the H5N1/VN antigens, good
levels of cross reactivity were seen, while the New Caledonia
H1N1 antigen (H1N1/NC) was a poor stimulant (Fig. 5A). A
peptide pool of 15mers spanning the whole N1 sequence of CA/07
Table 3. Geometric mean neutralization (NT) and hemagglutination inhibitions (HI) titers of mouse sera after single dose
immunizations with the live vectors.
Gr Vaccine Dose Day 7
(1) [NT/HI] Day 14 [NT/HI] Day 21 [NT/HI] Day 28 [NT/HI] Day 35 [NT/HI] Day 42 [NT/HI] Day 70 [NT/HI]
1 MVA-H1-Ca 10
6 ,dl/,dl ,dl/14 80/40 57/67 320/80 160/113 453/226
2 MVA-H1-Ca 10
7 ,dl/,dl ,dl/10 40/40 28/57 160/80 160/95 320/160
3 MVA-H1-Ca 10
8 ,dl/10 20/20 80/80 113/113 226/160 160/160 640/320
4 rVV-L-H1-Ca 10
6 ,dl/,dl ,dl/,dl 57/28 40/57 80/113 57/80 453/160
5 rVV-L-H1-Ca 10
7 ,dl/40 40/57 20/80 160/113 160/226 640/226 1280/226
6 rVV-L-H1-Ca 10
8 28/57 113/80 28/160 226/160 320/226 320/320 1810/320
7 MVA-wt
(2) 10
6 ,dl/,dl ,dl/,dl ,dl/,dl ,dl/,dl ,dl/,dl ,dl/,dl ,dl/,dl
8 PBS — ,dl/,dl ,dl/,dl ,dl/,dl ,dl/,dl ,dl/,dl ,dl/,dl ,dl/,dl
(1)day 0 titers were all below the detection limit (dl);
(2)wild-type MVA (NIH74 LVD clone 6); detection limits of the HI and the NT assay were ,10.
doi:10.1371/journal.pone.0012217.t003
Figure 3. Survival of SCID mice after passive transfer of
immune sera. A) Groups of three mice were infected intranasally
with doses of H1N1 wild-type virus in the range of 10
2 to 10
5 TCID50
per animal and monitored over a 32 day period. The 10
4 and 10
5 doses
were fully lethal. With the lower doses, mice survived the monitoring
period. B) Passive transfer of mouse sera and challenge with a dose of
10
5 TCID50 of H1N1 wild-type virus. All SCID mice receiving the sera of
Balb/c mice vaccinated with MVA-H1-Ca were protected, while the
MVA-wt controls all died.
doi:10.1371/journal.pone.0012217.g003
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proteinaceous antigen. Interestingly, a very strong CD8 T cell
response against N1 was also observed in mice vaccinated with the
N1-containing live vaccines (Fig. 5B). When using the N1 CA/07
peptide pool for stimulation of the cells, 3–4% of total CD8-T cells
were NA-specific, whereas the H1 peptide pool, used as a negative
control in this case, did not induce any IFN-c response.
7. Hemagglutinin-specific T cell responses in the lung
before and 3 days after intranasal challenge with H1N1
swine flu virus
To analyze whether the live vaccines, besides inducing high
levels of influenza-specific CD4 and CD8 T-cells in the spleen
shortly after booster immunization, also give rise to significant
levels of HA-specific T-cells at the site of influenza infection,
influenza-specific interferon c-secreting T cells were also quanti-
fied in the lungs. Mice (5 per group) were immunized twice (at
days 0 and 21) with the hemagglutinin constructs (MVA-H1-Ca
and rVVL-H1-Ca), and with the MVA wt control (10
6 pfu per
animal). The challenge with H1N1 wt virus was carried out at day
42. Subsequently the pre- and post challenge lung T cells were
analysed. For comparison reasons, T-cell responses were also
measured at the same time points in the spleens, a site not directly
involved in viral infection.
Seven days after the second immunization, and one day before
and three days after the challenge (at days 28, 41 and 44), lungs
Figure 4. T cell induction by the hemagglutinin expressing live vaccines. A) Frequencies of influenza antigen specific IFN-c+ CD4 T cells
after immunizing two times with hemagglutinin constructs MVA-H1-Ca (black bars), rVVL-H1-Ca (white bars) or inactivated vaccine (grey bars) and
stimulation with different antigens and peptides (shown on x-axis). Splenocytes were stimulated with buffer and with protein antigens (formalin-
inactivated monovalent bulk material) of the influenza strains H1N1 California (H1N1/CA), H1N1 Brisbane (H1N1/BR), H1N1 New Caledonia (H1N1/NC),
H5N1 Vietnam 1203 (H5N1/VN) and with peptide pools of overlapping 15-mer peptides of the swine flu hemagglutinin (H1/CA PP) or neuraminidase
(N1/CA PP) antigens. B) Frequencies of influenza hemagglutinin-specific IFN-c+ CD8 T-cells after two dosages of vaccine. Splenocytes were stimulated
with the peptide pools indicated above. The data are mean values (+/2 SEM) of two independent experiments.
doi:10.1371/journal.pone.0012217.g004
Figure 5. T cell induction by the neuraminidase expressing live vaccines. A) Frequencies of influenza antigen specific IFN-c+ CD4 T cells
after immunizing two times with MVA-N1-Ca (black bars), rVVL-N1-Ca (white bars) or inactivated vaccine (grey bars) and stimulation with buffer and
with different antigens and peptides (shown on x-axis). Splenocytes were stimulated with protein antigens as described in the legend of Fig. 4. B)
Frequencies of influenza neuraminidase-specific IFN-c+ CD8 T-cells after two dosages of vaccine. Splenocytes were stimulated with the peptide pools
indicated in the legend of Fig. 4. The data are mean values (+/2 SEM) of two independent experiments.
doi:10.1371/journal.pone.0012217.g005
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were flushed in-vivo with a heparin-containing medium to remove
blood cells (that might have an impact on lung-specific T cell
counts) and lungs and spleens were collected. Single cell
suspensions were prepared from 5 pooled lungs or spleens of
immunized mice. Pulmonary and spleen cells were stimulated with
the HA- and the control peptide pools (H1/CA PP and N1/CA
PP, respectively) and subjected to FACS analysis. High frequencies
of influenza-specific CD4 and CD8 cells were induced by
vaccination with the MVA-based HA vaccine, not only in the
spleens but also in the lungs, although the frequencies were slightly
lower in the lungs (Fig. 6). Seven days after the booster
immunization, approximately 1% of the lung CD4 T cells
(Fig. 6A) and 7% of the lung CD8 T-cells (Fig. 6B) were HA-
specific. Two weeks later, levels of T-cells had consistently
dropped by 40–50% in both lungs and spleens. Interestingly,
however, three days after the challenge, a five-fold increase in
IFN-c expressing HA-specific CD4 T cells was found only in the
lungs. In contrast, depletion of the spleens from influenza specific
CD4 T-cells was observed at that time point, within three days
after infection CD4 frequencies have dropped by 60% (Fig. 6A).
A similar picture was seen for the CD8 T cells. Before challenge,
about 3% of the CD8 pulmonary T cells were HA-specific, and a
two-fold increase was detected after challenge with H1N1 wt virus
at day 45, whereas the CD8 T-cell frequency in the spleens
decreased by 50%. The NA peptide pool (N1/CA PP), used as a
control in this experiment, induced only background levels of T
cells, demonstrating that little or no T-cells induced by the
infection with the swine virus were present in the lungs three days
after challenge. Therefore, the observed increase of influenza-
specific T-cells in the lungs upon challenge presumably reflects
influx of the HA-specific effector T-cells from other sites into the
lung.
Consistent results were obtained in mice immunized with rVV-
H1-Ca live vaccine. Also in this group, a pronounced rise in
influenza-specific CD4- (Fig. 6C) and CD8 T-cells (Fig. 6D) was
observed after challenge with swine influenza virus. As expected,
immunization with the MVA wt control did not induce any
influenza-specific T-cells in the lungs before and after challenge.
This clearly demonstrates that functionally competent effector T-
cells were induced by the vaccine which were capable of homing
into virus-infected tissue such as the lungs.
Discussion
Nonreplicating poxviruses have been used recently as potential
pandemic live vaccines against H5N1 influenza [23,24,25,26,
27,28]. In the current study, experimental vaccinia-based pandemic
H1N1 influenza live vaccines expressing either the hemaglutinin or
the neuraminidase of the novel swine H1N1 influenza strain were
analysed. The hemagglutinin containing vaccines were almost fully
protective in active immunizations, and protected animals had high
pre-challenge HI and neutralizing antibody titers against the wild-
type A/California/07/2009(H1N1) strain. The neuraminidase
containing MVA viruses were partially protective and neuramin-
idase-inhibiting antibodies were detectable, consistent with earlier
findings indicating that anti-NA antibodies do not neutralize
influenza virus but interfere with virus release from the host cells
resulting in reduction of titers [29]. After single dose vaccinations
only the HA-containing live vaccines induced protection from virus
in the lungs, presumably supported also by the strong T cell
responses induced by these vaccines. Since both antigens contrib-
uted substantially to immunity, a bivalent vector might be the
preferred choice as a pandemic vaccine.
Clear evidence exists that both CD4 and CD8 T cells
contribute to viral clearance of influenza in the lungs of mice
and thus contribute to protection [30,31] and more recent work
in chicken suggests, that pulmonary cellular immunity is very
important in protecting naive natural hosts against lethal H5N1
influenza viruses [32]. T-cell responses to natural influenza
infections are mainly directed against common epitopes on the
nucleoprotein, PB2 and M1 but also, to a lesser degree, against
the highly variable hemagglutinin and the neuraminidase [2] and
thus, in contrast to the generally type-specific protection of
antibodies against HA and NA, have the potential to provide
broad, heterosubtypic protection. Indeed, vaccines would be
preferable which, besides inducing a strong and stable humoral
immune response, also induce a strong anti-influenza cellular
response [33].
The MVA-based live vaccines induced surprisingly high
amounts of CD8 T cells, with both the HA and the NA constructs
giving rise to 4–5% of total antigen-specific CD8 T cells in
splenocytes 7 days after the second immunization. Further, the
levels of HA antigen-specific INF-c producing CD4 T cells were
also higher after immunization with the live vaccines. Consider-
able levels of CD4 T cells cross-reacting with related H1 strains
Figure 6. T cell induction by the hemagglutinin expressing live
vaccines in the lungs. Frequencies of influenza antigen specific IFN-
c+ CD4 T-cells (A, C) and CD8 T-cells (B, D) after immunizing two times
with hemagglutinin constructs MVA-H1-Ca (A, B) or rVVL-H1-Ca (C, D)
and stimulation with hemagglutinin (H1/CA-PP) or neuraminidase (N1/
CA-PP) peptide pools. Lung cells or spleen cells were isolated at days
28, 41 and 45. Animals were challenged with wild-type swine flu virus
on day 42, as indicated by the arrow. The filled (open) circles indicate
lung (spleen) cells stimulated with the hemagglutinin peptide pool H1/
CA PP. The filled (open) triangles indicate lung (spleen) cells stimulated
with the neuraminidase peptide pool used as negative controls.
Representative results of two independent experiments are shown.
doi:10.1371/journal.pone.0012217.g006
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seen. CD4-T cells induced by the recombinant N1 vectors also
cross-reacted with neuraminidase from seasonal H1N1 strains,
and, interestingly, from the avian VN1203 H5N1 strain.
Furthermore, high levels of HA-specific CD4 and CD8 T-cells
were detected in the lungs of mice immunized with the MVA-HA
vaccine construct at the time of challenge with wild type H1N1/
CA virus, with a further accumulation of effector T-cells observed
in the lungs three days after the challenge. Accumulation of
specific effector T-cells in the lungs of infected mice has been
shown to depend on differential expression of homing receptors
such as CD44 or CD62L [34], which target the cells from the
lymphoid tissue to non-lymphoid organs. However, upon
pulmonary infection with influenza virus, IFN-c secreting CD8
T-cells can be detected only after 5 days in the lungs [35] whereas,
after immunization with MVA-H1, they are present already in
high frequencies before infection, and, upon infection, enter the
lungs much more rapidly by relocation from other sites such as the
spleen. These influenza-specific effector T-cells present at the site
of infection have the potential to contribute to protection in
various ways, for instance, by inhibition of viral replication, by
secretion of cytokines, by direct killing of virus-infected host cells,
or by support of influenza specific B-cells. Interestingly, in Balb/c
mice, the primary pulmonary CD8 T cell response against
influenza A/Japan/305/57(H2N2) was mainly directed against
three epitopes in the HA and one in the NP [35], suggesting that
CD8 T cell responses are strongly dependent on the infecting virus
strain and the host genetic background. Moreover, lung-resident
proliferation contributes significantly to the magnitude of the Ag-
specific CD8 T cell response following influenza virus infection
[36].
A further advantage of using MVA as pandemic influenza
vaccine is its genetic stability including that of the expressed
foreign genes. Passage of influenza primary isolates in eggs usually
results in adaptive mutations in the HA gene. When non egg-
adapted human influenza virus, i.e., either the natural virus
present in a clinical specimen or an isolate propagated exclusively
in tissue culture cells, is first passaged in the allantoic cavity of
embryonated hens’ eggs, variants which have amino acid
substitutions around the receptor binding site are selected [37].
Therefore, egg adaption can result in altered antigenicity which
can result in reduced protection [2]. To preserve the original
genotype of viruses used as reference strains, a complex procedure
is recommended, involving cloning in chicken eggs of the
candidate virus at a very early passage, selection and analysis
with appropriate antibodies and selection of the isolate whose
hemagglutinin molecule most closely resembles the clinical isolate
[38]. All these complications are overcome if a stable DNA virus,
such as MVA, is used as a vector for the influenza genes. This
vector is independent of influenza virus-specific selection mecha-
nisms and thus, the originally inserted sequences do not change
resulting in preservation of the originally inserted HA or NA
genes.
MVA-based pandemic vaccines may also have advantages as
compared to cold-adapted live influenza vaccines. In a recent
evaluation of live attenuated cold-adapted H5N1 influenza virus
vaccines in healthy adults, HI and neutralizing antibody responses
were found to be minimal [8]. Several reasons were identified for
this failure: the attenuating mutations specified by the A/Ann
Arbor/6/60 (H2N2) cold-adapted virus loci had the greatest
influence, followed by the deletion of the H5 HA multi-basic
cleavage site (MBS) and the constellation effects of the internal
backbone genes acting in concert with the H5N1 glycoproteins
[9]. In poxviral vectors, these influenza virus-specific effects do not
play a role. Injection of defined amounts of a stable vector results
in reliable delivery, moreover the use of strong vaccinia promoters
and optimized foreign genes result in high-level expression and
good induction of B and T cell responses. In addition, MVA
tolerates pre-existing anti-vaccinia immunity and can be used as
an immunizing agent under conditions of pre-existing immunity to
the vector and thereby may allow repeated use [39].
Furthermore, full protection of SCID mice was achieved after
passive transfer of sera from MVA-H1-Ca immunized mice while
the control mice, challenged with a dose of 1610‘5 TCID50 of wt
CA/07 virus died within three weeks from pneumonia with titers
of 5–6 log10 TCID50 being found in the lungs. Interestingly,
despite lack of clinical symptoms in the protected SCID mice, virus
was found at the end of the 4 week monitoring period in the
majority of lungs. This indicates that a single prophylactic dose of
antiserum given prior to challenge was not sufficient for virus
clearance. However, as shown previously by others [40], infection
of SCID mice with A/PR8/34(H1N1) influenza virus followed by
passive transfer of two doses of an anti-hemagglutinin antibody
cocktail at days 2 and 6 had lead to clearance and full recovery
from infection. Thus, protection including clearance of virus, may
be achieved by a higher dose and by repeated dosing of the
antiserum. Furthermore, in the case of H1N1 CA/07 virus, full
protection of SCID mice was obtained after passive transfer of sera
generated with the inactivated whole virus vaccine in mice and
guinea pigs [16].
In conclusion, the mouse data presented here suggest that
modified vaccinia Ankara-based recombinant viruses, besides
demonstrated safety, have some further advantages as pandemic
influenza vaccines, including excellent induction of both antibody
and T cell responses, genetic stability of the hemagglutinin due to
independence from influenza-specific genetic alterations and
efficacy after single dose vaccination. Our study shows that
MVA is a good alternative as pandemic influenza vaccine against
the novel H1N1 subtype, in accordance with previous studies
demonstrating that corresponding MVA recombinants also
protect against avian H5N1 strains [23,24]. The H1N1 pandemic
strain currently causes mild disease presumably due to partial
immunity mainly in the adult population. If - similar to the 1918
pandemic - more virulent mutants would occur in subsequent
waves of infection, more broadly protecting vaccines would be
desirable.
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